BORTEZOMIB vs KYPROLIS

Independent side-by-side comparison.

Rated against independent regulatory sources·Last updated June 7, 2026·How we rate

Possible drug interaction. BORTEZOMIB and KYPROLIS are different prescription medicines. Combining or switching between them can cause interactions — talk to a pharmacist or prescriber before making changes. This page is not medical advice.

Attribute	BORTEZOMIB	KYPROLIS
Rating	New	New
Pharmacy pays	—	—
Type	RX	RX
Active ingredient	BORTEZOMIB	CARFILZOMIB
Manufacturer	Accord Hlthcare	Onyx Pharms Amgen
Dosage forms	Injectable, Powder	Injectable
Drug class	Proteasome Inhibitor	Proteasome Inhibitor
Boxed warning	None	None
Treats	Multiple Myeloma, Mantle-Cell Lymphoma	Multiple Myeloma

bortezomib kyprolis

Rating

New

Pharmacy pays

—

Type

Active ingredient

BORTEZOMIB

CARFILZOMIB

Manufacturer

Accord Hlthcare

Onyx Pharms Amgen

Dosage forms

Injectable, Powder

Injectable

Drug class

Proteasome Inhibitor

Boxed warning

None

Treats

Multiple Myeloma, Mantle-Cell Lymphoma

Multiple Myeloma

Frequently asked questions

What is the difference between Bortezomib and Kyprolis?

Bortezomib contains Bortezomib, while Kyprolis contains Carfilzomib — they have different active ingredients.

Ratings are based on FDA regulatory (recall-safety) data. This comparison is for general reference only — not medical advice. Always consult a licensed professional before choosing or switching a medication.